40,606 Shares in HCA Healthcare, Inc. $HCA Acquired by Townsend & Associates Inc

Key Points

• Townsend & Associates Inc acquired 40,606 shares of HCA Healthcare, valued at approximately $15.56 million, making it the company's 24th largest holding.
• HCA Healthcare reported $6.84 earnings per share for the last quarter, surpassing expectations, and set its FY 2025 guidance between 25.500-27.000 EPS.
• Institutional investors currently own 62.73% of HCA Healthcare's stock, signaling strong support from the investment community.

Townsend & Associates Inc acquired a new position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,606 shares of the company's stock, valued at approximately $15,556,000. HCA Healthcare makes up about 1.6% of Townsend & Associates Inc's investment portfolio, making the stock its 24th biggest holding.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in HCA Healthcare during the 4th quarter valued at $1,021,000. GAMMA Investing LLC boosted its position in HCA Healthcare by 17.6% during the 1st quarter. GAMMA Investing LLC now owns 4,931 shares of the company's stock valued at $1,704,000 after acquiring an additional 737 shares in the last quarter. ORG Partners LLC boosted its position in HCA Healthcare by 344.0% during the 1st quarter. ORG Partners LLC now owns 111 shares of the company's stock valued at $38,000 after acquiring an additional 86 shares in the last quarter. Castleview Partners LLC bought a new stake in HCA Healthcare during the 1st quarter valued at $223,000. Finally, World Equity Group Inc. boosted its position in HCA Healthcare by 9.7% during the 1st quarter. World Equity Group Inc. now owns 1,538 shares of the company's stock valued at $531,000 after acquiring an additional 136 shares in the last quarter. Institutional investors own 62.73% of the company's stock.

HCA Healthcare Stock Performance

Shares of HCA opened at $425.50 on Monday. The stock has a 50-day moving average of $410.05 and a two-hundred day moving average of $378.63. The stock has a market cap of $99.56 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.35 and a beta of 1.40. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $439.01.

HCA Healthcare (NYSE:HCA - Get Free Report) last released its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. The business had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The company's revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the business posted $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th were paid a dividend of $0.72 per share. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio (DPR) is presently 12.11%.

Insider Buying and Selling at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. The trade was a 10.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HCA has been the subject of a number of recent analyst reports. Barclays raised their price objective on HCA Healthcare from $390.00 to $445.00 and gave the stock an "overweight" rating in a research report on Thursday, September 18th. Morgan Stanley lowered their price objective on HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a research report on Monday, July 28th. Robert W. Baird raised their price objective on HCA Healthcare from $380.00 to $423.00 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. Jefferies Financial Group raised their price objective on HCA Healthcare from $400.00 to $485.00 in a research report on Wednesday, October 15th. Finally, KeyCorp lifted their price target on HCA Healthcare from $370.00 to $465.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $437.19.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.